Michael C. Heinrich

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors

Biology of Gastrointestinal Stromal Tumors

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor

Gastrointestinal stromal tumour

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>

Gastrointestinal stromal tumours: origin and molecular oncology

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo